Kyowa Kirin Co., Ltd. (TYO: 4151)
Japan
· Delayed Price · Currency is JPY
2,375.50
-17.00 (-0.71%)
Dec 20, 2024, 3:45 PM JST
Kyowa Kirin Revenue
Kyowa Kirin had revenue of 129.82B JPY in the quarter ending September 30, 2024, with 21.51% growth. This brings the company's revenue in the last twelve months to 498.98B, up 18.62% year-over-year. In the year 2023, Kyowa Kirin had annual revenue of 442.23B with 11.01% growth.
Revenue (ttm)
498.98B
Revenue Growth
+18.62%
P/S Ratio
2.54
Revenue / Employee
83.52M
Employees
5,974
Market Cap
1,209.08B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 442.23B | 43.86B | 11.01% |
Dec 31, 2022 | 398.37B | 46.13B | 13.09% |
Dec 31, 2021 | 352.25B | 33.89B | 10.65% |
Dec 31, 2020 | 318.35B | 12.53B | 4.10% |
Dec 31, 2019 | 305.82B | -40.71B | -11.75% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionKyowa Kirin News
- 12 days ago - Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies - Business Wire
- 4 weeks ago - Kura stock slides 17% on Kyowa Kirin deal for ziftomenib - Seeking Alpha
- 4 weeks ago - Kura Oncology to partner with Kyowa Kirin for blood cancer therapy - Reuters
- 7 weeks ago - Kyowa Kirin 9M GAAP EPS of Yen 105.19, revenue of Yen 362.8B - Seeking Alpha
- 7 weeks ago - Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company - Business Wire
- 2 months ago - Kyowa Kirin Announces Positive Interim Real-world Data for Mogamulizumab (Poteligeo®) in Cutaneous T-cell Lymphoma at EORTC-CLTG 2024 - Business Wire
- 3 months ago - Kyowa Kirin Announces Top-line Data from Rocatinlimab Phase 3 ROCKET HORIZON Trial for Adults with Moderate to Severe Atopic Dermatitis - PRNewsWire
- 3 months ago - Kyowa Kirin to Present New Research Spotlighting Global Efforts to Advance Science and Patient Care in X-linked Hypophosphatemia at ASBMR Annual Meeting - PRNewsWire